Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Upfront and milestone payments received to date | $ 110.0 | |
| Revenue recognized by the Company | 0.0 | $ 3.7 |
| Company received a reimbursement for eligible worldwide development expenses | $ 0.8 | $ 2.0 |
| Collaborative Arrangement Product Agreement | Evofosfamide | ||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Merck KGaA's percentage share of worldwide development expenses | 70.00% | |
| X | ||||||||||
- Definition Merck KGaA's percentage share of worldwide development expenses. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|